Fig. 9: Schematic diagram illustrates the TRIB3-UBE3B-MYC axis driving lymphoma development and progression. | Nature Communications

Fig. 9: Schematic diagram illustrates the TRIB3-UBE3B-MYC axis driving lymphoma development and progression.

From: TRIB3 promotes MYC-associated lymphoma development through suppression of UBE3B-mediated MYC degradation

Fig. 9

TRIB3 expression is enhanced in human lymphoma cells due to either the increased copy number in response to various stresses and nonsynonymous (Q84R) mutation of TRIB3. Whereas, UBE3B, an E3 ubiquitin ligase, and UBCH3, an E2 ubiquitin-conjugated enzyme, have been identified to target MYC for proteasomal degradation. The enhanced TRIB3 interacts with MYC to decrease the UBE3B-mediated ubiquitination of MYC K427 and increase MYC stability; this interaction also supports the formation of MYC and MAX heterodimer. These actions enhance MYC transcriptional activity, causing high proliferation and self-renewal of lymphoma cells. Interfering with the TRIB3/MYC interaction enhances MYC degradation and suppresses the development and progression of high TRIB3/MYC-associated lymphoma.

Back to article page